Spain’s 2025–2027 Strategy to Drive Innovative, Resilient Healthcare and Industry

The Strategic Program for Cutting-Edge Healthcare 2025-2027, approved by the Government of Spain, ensures the continuity of the Cutting-Edge Healthcare Program with the aim of consolidating a healthcare and industrial model based on innovation, science, and the strengthening of strategic capabilities.

The document defines the framework that will guide public and public-private actions in healthcare during the 2025-2027 period, aligning healthcare policy with the objectives of economic growth and industrial strengthening.

The Program in Spain is based on a general objective that combines two inseparable dimensions: improving the health of the population and generating opportunities for economic and industrial development in Spain. To this end, it positions biomedical research, technological innovation, digitalization, and production capacity as key elements for transforming the healthcare system, explicitly integrating the pharmaceutical, biotechnology, and medical technology industries as strategic partners.

Based on this foundation, the Strategic Program identifies a series of strategic objectives that structure its implementation, ranging from the evolution towards advanced healthcare models to the strengthening of the manufacturing of medicines and critical technologies. These objectives are conceived as interrelated, so that advances in personalized medicine, digitalization, and preparedness for global threats are supported by a solid base of industrial, scientific, and technological capabilities.

Alongside these strategic objectives, the Program incorporates cross-cutting objectives aimed at strengthening R&D&I capabilities, knowledge transfer, industrial competitiveness, strategic autonomy, and human capital development. Taken together, the document establishes a roadmap that guides public health policies toward a more innovative, resilient model with greater value creation capacity, upon which the Program’s various strategic axes are further developed.

Personalized medicine as a driving force in Spain healthcare sector

The first strategic objective focuses on promoting personalized, predictive, preventive, participatory, and population-based medicine (5P) . The program emphasizes the need to move from models focused exclusively on disease to approaches based on prevention , prediction, and patient stratification , with a direct impact on the development of medicines and diagnostic solutions.

This objective encompasses strengthening capabilities for biomedical research , the development of advanced therapies and the use of biomarkers, as well as integrating these advances into clinical practice. From an industrial perspective, the program links this focus to the generation of applicable knowledge , the transfer of results, and the development of high value-added products.

Development and manufacturing of innovative medicines

The second strategic objective focuses on the development and manufacture of biotechnology products, healthcare technologies, and innovative medicines —an area of ​​particular importance to the pharmaceutical industry. The program identifies the need to strengthen national production capacity , modernize industrial processes, and facilitate the scaling up of innovation.

The document highlights the importance of having advanced industrial infrastructure capable of covering the entire drug lifecycle, from research to manufacturing. This objective is also linked to attracting investment, strengthening the business sector, and promoting projects that contribute to strategic autonomy in medicines and technologies considered critical.

Digitization, data and artificial intelligence

The third strategic objective addresses the development of digital healthcare services, health data spaces and their analytics, including the use of artificial intelligence, always under conditions of cybersecurity and data governance. The program presents this axis as a key element for improving the efficiency of the healthcare system and accelerating innovation.

In Spain’s industrial sector, access to high-quality data and its secure use are identified as key drivers for improving clinical research , optimizing drug development, and generating new data-driven innovation models. The objective also includes interoperability and the creation of environments that facilitate public-private collaboration.

Preparedness for threats and health security

The fourth strategic objective focuses on preparedness and response to global health threats , as well as strengthening health security. The program incorporates industrial capabilities as an essential component to ensure the availability of medicines, vaccines, and health technologies in crisis situations.

This objective reinforces the idea that national productive capacity of Spain is a strategic element of the health system, integrating industry as an active part of the response to health emergencies and risks.

Cross-cutting objectives with industrial impact

Alongside its strategic objectives, the Strategic Program for Cutting-Edge Healthcare 2025-2027 defines a series of cross-cutting objectives that reinforce its industrial dimension. Among these, the promotion of R&D&I capabilities in healthcare and their transfer stands out , with the aim of improving the connection between research, technological development, and the market.

The program in Spain also includes strategic autonomy, competitiveness, and industrial modernization as cross-cutting objectives , aligning the Regional Program for Technological Innovation (PERTE) with national industrial priorities. This is complemented by a commitment to equity , international leadership , and the training, attraction, and retention of human capital , all considered critical factors for sustaining the growth of the healthcare industrial ecosystem.

__

(Featured image by jarmoluk via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.